We serve Chemical Name:Zirconium tungstate CAS:16853-74-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Zirconium tungstate
CAS.NO:16853-74-0
Synonyms:TUNGSTEN ZIRCONIUM OXIDE;(metalsbasisexcludingHf),Hf;ditungsten zirconium octaoxide;MFCD00168096;Zirconium ditungstenoctaoxide;EINECS 240-876-3
Molecular Formula:O8W2Zr
Molecular Weight:586.89900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:160.52000
Exact Mass:585.76600
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like TUNGSTEN ZIRCONIUM OXIDE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,EINECS 240-876-3 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 240-876-3 Use and application,TUNGSTEN ZIRCONIUM OXIDE technical grade,usp/ep/jp grade.
Related News: Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. Zirconium tungstate manufacturer The Transport Security Administration (TSA) will issue a new security directive to airlines from Sunday, according to a person briefed on the restrictions. Zirconium tungstate supplier The Transport Security Administration (TSA) will issue a new security directive to airlines from Sunday, according to a person briefed on the restrictions. Zirconium tungstate vendor Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. Zirconium tungstate factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.
